pocketful logo light
pocketful logo light
Aurobindo Pharma Ltd logo

Aurobindo Pharma Ltd

NSE: AUROPHARMA BSE: 524804

₹1580.20

(0.25%)

Tue, 04 Aug 2026, 11:54 pm

Aurobindo Pharma Share Price Live Chart

1 Day

(0.25%)

No Result Found

Summary

  • Market Cap (in Cr)

    83106.9

  • Net Profit (in Cr)

    3483.57

  • P/B

    2.06

  • Sector P/E

    33.76

  • P/E

    19.32

  • EV/EBITDA

    9.39

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    11.15

  • ROCE

    14.16

  • Debt/Equity

    0.24

  • EPS (TTM)

    61.09

  • Dividend Yield

    0

  • Book Value

    652.39

  • Interest Cover

    12.08

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are thoroughly covered by earnings (11.4x coverage).
  • Dividends after 3 years are expected to be thoroughly covered by earnings (12x coverage).
  • Aurobindo Pharma's earnings growth is expected to exceed the low risk savings rate of 7.2%.
  • Aurobindo Pharma's earnings are expected to exceed the low risk growth rate next year.
thumbs up icon

Cons

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Aurobindo Pharma's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Aurobindo Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for Aurobindo Pharma is expected to decrease over the next 2 years.
  • Aurobindo Pharma's earnings are expected to grow by 9.7% yearly, however this is not considered high growth (20% yearly).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters51.8251.8251.8251.8251.82
FII15.2413.9414.2114.3715.33
DII25.8727.6827.6026.9326.23
Public7.086.556.386.876.61
Government0000.000.00

Read More

Technical Analysis

RSI

57.25

MACD

13.27

50 DMA

1515.51

200 DMA

1313.24

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1825.931701.131640.671576.331515.871451.531326.73
Fibonacci1701.131653.461624.011576.331528.661499.211451.53
Camarilla1614.521603.081591.641576.331568.761557.321545.88

Pivots Level: Classic

R3

+249.60

1825.93

R2

+124.80

1701.13

R1

+64.33

1640.67

1576.33
1576.33
Pivot Point
LTP: 1585.90

S1

-60.47

1515.87

S2

-124.80

1451.53

S3

-249.60

1326.73

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1565.63

  • 20-EMA

    1556.83

  • 30-EMA

    1546.00

  • 50-EMA

    1519.76

  • 100-EMA

    1451.78

  • 200-EMA

    1360.94

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
21 May 2026board-meetingsAccounts
06 Apr 2026buyback
09 Feb 2026board-meetingsQuarterly Results, Nine Months Results
05 Nov 2025board-meetingsQuarterly Results
12 Aug 2025agm
04 Aug 2025dividend₹4.00 Dividend /Share08 Aug 2025
08 Jul 2025dividendInterim Dividend - Rs. - 408 Aug 2025
30 Jul 2024agm
26 Jul 2024agmAnnual General Meeting27 Aug 2024
18 Jul 2024buyback

Read More

Peer Comparison

Aurobindo Pharma Ltd logo

Aurobindo Pharma Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Cipla Ltd logo

Cipla Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Aurobindo Pharma Ltd About

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1986

Headquarters

CEO

M R Kumar

Employees

Contact

Website icon

Website

http://www.aurobindo.com

Email icon

Email

cs@aurobindo.com; investorgrievances@aurobindo.com

Phone icon

Phone

91-40-23736370

Location icon

Location

Plot No 2 Maitrivihar, Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, 500038

Read More

Aurobindo Pharma Ltd Company History

YearHistory
2020
  • Tied up with BIRAC to develop COVID-19 vaccine.
  • Collaborated with CSIR to develop COVID-19 vaccine.
  • Signed exclusive licensing agreement with COVAXX.
2021
  • Received USFDA approval for Droxidopa Capsules.
  • Received NCLT approval for scheme of amalgamation.
2022
  • Acquired 51% stake in GLS Pharma Limited.
  • Arm received final USFDA approval for Vasopressin injection.
  • Arm received USFDA approval for Triamcinolone Acetonide injectable suspension.
2023
  • Arm received USFDA approval for cancer drug.
  • To launch HIV triple combination product for children under ViiV Healthcare licence.
2024
  • Received first USFDA approval for Lidocaine Hydrochloride Injection.
  • Commissioned four plants in Andhra Pradesh including Pen-G facility.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GOLDMAN SACHS (SINGAPORE) PTE.- ODIblockSell106228110716 Oct 2025
GOLDMAN SACHS BANK EUROPESE - ODIblockBuy106228110716 Oct 2025
MARSHALL WACE INVESTMENT STRATEGIES SYSTEMATIC ALPHA PLUS FUNDblockBuy8621160.125 Jan 2024
SOCIETE GENERALEblockSell1075581160.125 Jan 2024
SOCIETE GENERALEblockBuy14843231160.125 Jan 2024
BNP PARIBAS ARBITRAGEblockSell14843231160.125 Jan 2024
MARSHALL WACE INVESTMENT STRATEGIES EUREKA FUNDblockBuy536411160.125 Jan 2024
MARSHALL WACE INVESTMENT STRATEGIES - EUREKA FUNDblockBuy1064801160.125 Jan 2024
MARSHALL WACE INVESTMENT STRATEGIES MARKET NEUTRAL TOPS FUNDblockBuy81341160.125 Jan 2024
MARSHALL WACE INVESTMENT STRATEGIESGTOPS FUNDblockBuy275711160.125 Jan 2024

Read More

Aurobindo Pharma Ltd News

Aurobindo Pharma sets Aug 27 date for 39th AGM

Aurobindo Pharma Limited has scheduled its 39th Annual General Meeting for August 27, 2026. The meeting will be held via Video Conferencing. Share transfer books will remain closed on August 26 and 27.

29 Jul 2026

companies

Aurobindo Pharma Q1FY27 Earnings Call Schedule

Aurobindo Pharma Limited will host an analyst and investor call on August 6, 2026, at 8:30 AM IST to discuss its unaudited financial results for the first quarter ended June 30, 2026.

29 Jul 2026

companies

Aurobindo Pharma signs HIV drug license deal

Aurobindo Pharma Ltd has entered a royalty-free voluntary license with MSD to supply generic alimtravir to 129 low- and middle-income countries, marking a first in pre-phase 3 licensing for HIV prevention.

24 Jul 2026

companies

Aurobindo Pharma subsidiary buys 80% stake in A1 Biochem

Apitoria Pharma, a wholly owned subsidiary of Aurobindo Pharma, has approved the acquisition of an 80% stake in A1 Biochem Group for USD 17 million. The deal aims to build a CRDMO platform.

23 Jul 2026

companies

Aurobindo Pharma unit gets Brazil ANVISA nod

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, received ANVISA approval for its Hyderabad facility. The approval covers biosimilar manufacturing for Brazil and Latin America.

21 Jul 2026

companies

Read More

Frequently Asked Questions

  • 1.What is the stock price of Aurobindo Pharma Ltd?

    As of 05/08/2026 at 5:24 AM, Aurobindo Pharma Ltd shares are trading at ₹1580.20.

  • 2.What is the market cap. of Aurobindo Pharma Ltd?

    As of 05/08/2026, the market capitalization of Aurobindo Pharma Ltd is ₹90,872.30 crore.

  • 3.When was Aurobindo Pharma Ltd founded?

    Aurobindo Pharma Ltd was founded in 1986.

  • 4.What are the P/E and P/B ratios of Aurobindo Pharma Ltd?

    As of 05/08/2026, Aurobindo Pharma Ltd has a P/E ratio of 26.19 and a P/B ratio of 2.06.

  • 5.How can I buy shares of Aurobindo Pharma Ltd?

    You can buy shares of Aurobindo Pharma Ltd through Pocketful. Simply open a Demat account, complete your KYC, add funds, and place a buy order.

  • 6.What is the shareholding pattern of Aurobindo Pharma Ltd?

    As of March,2026, promoters hold 51.82% in Aurobindo Pharma Ltd, while FIIs, DIIs and public shareholders hold 15.24%, 25.87% and 7.08%, respectively.

  • 7.Does Aurobindo Pharma Ltd pay dividends?

    Yes, Aurobindo Pharma Ltd pays dividends to eligible shareholders. The latest dividend announced by the company was ₹₹4.00 Dividend /Share per share.

  • 8.What is the dividend yield of Aurobindo Pharma Ltd?

    As of 05 August, 2026, the dividend yield of Aurobindo Pharma Ltd stands at 0.25%.

  • 9.What are the latest financial results of Aurobindo Pharma Ltd?

    For January,2024, Aurobindo Pharma Ltd reported revenue of ₹31,403.00 crore and a net profit of ₹3,486.00 crore.

  • 10.What is the Stock symbol of Aurobindo Pharma Ltd?

    AUROPHARMA is the stock symbol of Aurobindo Pharma Ltd.

  • 11.Who is the CEO of Aurobindo Pharma Ltd?

    The CEO of Aurobindo Pharma Ltd is M R Kumar.

Open Your Free Demat Account

Enter your phone number